atai Life Sciences Announces Launch of Initial Public Offering
June 11 2021 - 7:59AM
atai Life Sciences B.V. (“atai”), a clinical-stage
biopharmaceutical company aiming to transform the treatment of
mental health disorders, today announced the commencement of a
proposed underwritten initial public offering of 14,286,000 of its
common shares. All common shares to be sold in the proposed
offering will be sold by atai. The underwriters of the offering
will have a 30-day option to purchase up to an additional 2,142,900
common shares at the initial public offering price, less the
underwriting discounts and commissions. The initial public offering
price is expected to be between $13.00 and $15.00 per common share.
atai has applied to list its common shares on the Nasdaq Global
Market under the ticker symbol “ATAI.”
Credit Suisse, Citigroup, Cowen, and Berenberg are acting as
book-running managers for the proposed offering. Cantor, RBC
Capital Markets and Canaccord Genuity are also acting as
book-running managers for the proposed offering.
The offering will be made only by means of a prospectus. A copy
of the preliminary prospectus relating to this offering, when
available, may be obtained by contacting Credit Suisse Securities
(USA) LLC, Attention: Prospectus Department, 6933 Louis Stephens
Drive, Morrisville, NC 27560, or by telephone at (800) 221-1037 or
by email at usa.prospectus@credit-suisse.com; Citigroup Global
Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island
Avenue, Edgewood, NY 11717, or by telephone at (800) 831-9146 or by
email at prospectus@citi.com; Cowen and Company, LLC, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
New York 11717, Attention: Prospectus Department, or by telephone
at (833) 297-2926, or by email at
PostSaleManualRequests@broadridge.com; or, Berenberg Capital
Markets LLC, Attention: Investment Banking, 1251 Avenue of the
Americas, 53rd Floor, New York, New York 10020, or by telephone at
+1 (646) 949-9000, or by e-mail at
prospectusrequests@berenberg-us.com.
A registration statement on Form S-1 relating to these
securities has been filed with the U.S. Securities and Exchange
Commission (the “SEC”) but has not yet become effective. These
securities may not be sold nor may offers to buy these securities
be accepted prior to the time the registration statement becomes
effective. This press release shall not constitute an offer to sell
or the solicitation of an offer to buy, nor shall there be any sale
of, these securities in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of such
state or jurisdiction.
About atai Life Sciences atai is a
clinical-stage biopharmaceutical company aiming to transform the
treatment of mental health disorders. atai was founded in 2018 as a
response to the significant unmet need and lack of innovation in
the mental health treatment landscape, as well as the emergence of
therapies that previously may have been overlooked or underused,
including psychedelic compounds and digital therapeutics. atai is
headquartered in Berlin, with offices in New York and London.
Investor Contact:
Greg Weaver
atai – Chief Financial Officer
Email: greg.weaver@atai.life
Media Contact:
Anne Donohoe
KCSA Strategic Communications
Phone: +1 (212) 896-1265
Email: atai@KCSA.com
ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From Jun 2024 to Jul 2024
ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From Jul 2023 to Jul 2024